Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q40481231

about

Stem cell transplantation in chronic lymphocytic leukemia Fludarabine in the treatment of chronic lymphocytic leukemia: a review Alemtuzumab for B-cell chronic lymphocytic leukemia.The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101 Role of fludarabine in hematological malignancies.A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response Fludarabine in chronic lymphocytic leukaemia.Treatment options for high-risk chronic lymphocytic leukaemia.Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?Monoclonal antibody-based therapeutics for leukemia.Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?Emerging therapy for chronic lymphocytic leukaemia.Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Pharmacokinetics of alemtuzumab and the relevance in clinical practice.Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.Modern concepts in the treatment of chronic lymphocytic leukemia.Changing paradigms in the treatment of chronic lymphocytic leukemia.Pediatric Dosing and Body Size in Biotherapeutics.What is the best frontline therapy for patients with CLL and 17p deletion?Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?What do we do with chronic lymphocytic leukemia with 17p deletion?Shifting paradigms in the treatment of chronic lymphocytic leukemia.Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.

P2860

Q24642921-21A2E8EC-4909-4179-B590-9A9BE571072B Q24645173-4EFA30C2-7422-4AAE-B5F0-DE303F016A3A Q33380135-663436AF-277C-4DCB-B808-281C8A1B8287 Q33558740-95EBE39A-DC4A-4118-9859-F146850B6633 Q33956034-E9851A63-E9F8-4775-B8CA-15520FBCC8BC Q34334943-4BA805FC-F4D6-4447-BBE0-2C3E5BC9C7DB Q34571439-7B9E835E-514F-4272-A274-2CE2D7B7AAE9 Q35061729-9DEE1D51-7C7E-4FD3-9EB3-E9F81676E3DD Q35382716-7B3B9481-AC0F-434A-9172-9CF80D7B09AF Q35751049-29FFE579-0A12-4A48-8D45-B75ACAB8769F Q35951606-00689498-6A16-40E1-BB14-0231C6557121 Q36024673-41C9A9C7-E52A-427E-97DB-3442B20F9F96 Q36548735-756452BF-45ED-4154-B43C-838856B06851 Q36612587-95DDF7D6-84BB-4C8A-AFCD-ED22AA012CD6 Q36665330-73595AD7-B12C-4972-9E1A-63FBC7473FF6 Q36739759-898BE462-070E-43A8-AEA2-29A16442D046 Q36832113-4BCD110B-B3F5-4AFB-ABF2-584DF54D353E Q36952609-DE31F868-6C56-446F-B67C-B456FA7C88A5 Q36981738-393212ED-23D4-4835-B1FA-ACC01F76AA85 Q36985872-D9158FC2-6E31-4BB9-82D1-C8D2F16D4BA5 Q37004820-2B593F75-4103-4CFD-BBF7-94141B90034C Q37012037-5638ECAC-5098-4024-9CE6-C06ADDBF75A3 Q37134417-85DF1EAB-9803-438F-8E21-739170D1CF53 Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B Q37340406-14218CC5-964A-49A5-90E7-512E8F811CB1 Q37387647-C9CA5E25-8808-4F00-9222-645E8ED4D84A Q37559275-36F46B0B-0F2F-41CD-AA82-A05C61BBD4C7 Q37618337-9B96FE8E-55F5-4260-BEAB-7C63B59D06B0 Q37662198-8E62798A-6F2E-41AB-B76B-E4039E1ABD67 Q37666711-807BEE32-6E5C-44C8-AB69-BFCE4A52DAD4 Q37820433-AE0E42CB-B69A-4D11-A096-49096162032C Q37842484-7F82CEBD-57FE-4943-B763-D7E4E523A5EC Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F Q37975154-9B27D4E4-B031-4609-BC19-C0DD850ABE87 Q38063170-5496D13A-0C7A-4A73-ADC6-5DB9E40F7C98 Q38357127-BD5F2A97-08E3-46AC-8DDF-BAB8FE3DF28C Q38866636-7F041A0B-A2D6-4F87-BD29-D3AD04209086 Q39215476-CA200E04-11A9-41E4-B4FF-7B84F02C8BC8 Q39544646-5BA27F92-1A98-4363-8F87-7AC5351D8D8C Q39718346-2154B039-FD39-456C-BF8E-5FAE3A1329DF

P2860

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q40481231

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Alemtuzumab as consolidation a ...... chronic lymphocytic leukemia.

@en

type

label

Alemtuzumab as consolidation a ...... chronic lymphocytic leukemia.

@en

prefLabel

Alemtuzumab as consolidation a ...... chronic lymphocytic leukemia.

@en

P1433

Q40481231-0A38485F-2F91-41FF-ADA7-F8F09EB0013A

P1476

Q40481231-CFB462AC-7188-47CD-97A8-3FB9CF26A9C3

P2093

Q40481231-0C461DCA-2520-4301-A3F9-945A1C4F8479

Q40481231-208ED870-FE55-410A-B103-173AE8901A50

Q40481231-251B6BFC-3A0C-4ECD-BC6F-363EAABDD7E6

Q40481231-3697E8B1-22A3-4F25-8A48-0333F12F6461

Q40481231-5E0CE08B-4A38-42C2-AEB7-D78AB4F7D52C

Q40481231-79448882-D45A-4417-80D0-82CA0CB3BB18

Q40481231-8CFD8544-6DF4-469D-9FE1-D94AC7A8A018

Q40481231-B35C35D5-1A23-484D-94B9-B31C8B978EB7

Q40481231-CF16D546-8CA1-487A-9950-F3A8F56D8981

Q40481231-D430076C-1812-4449-AD85-67F803FCFE55

P304

Q40481231-77CEB557-1AD8-4A0E-9ADD-D653C5E8A3DB

P31

Q40481231-3BBD467A-8D94-4DE1-B61C-33DF9F7E4055

P356

Q40481231-AAEEA975-A114-4C87-A919-225142F28712

P407

Q40481231-9676AC95-5EC5-450E-B569-0F5B914149F0

P433

Q40481231-247B1C34-8680-4217-8240-DF6577807724

P478

Q40481231-23ABA332-BAC8-4423-93DD-B6ACA082B8CB

P50

Q40481231-084DCDC8-5445-4FF3-BF5E-17D58BE44F0E

P577

Q40481231-230B04F1-FA42-45F9-B35A-F22717F3FD34

P698

Q40481231-16AADCA7-65DF-412D-9712-4306C8C927E1

P921

Q40481231-1F96D73F-C2B8-4FA2-BF08-DC8C89E56EA1

Q40481231-59676FEB-D54D-499B-90E8-3B95EACF8F28

P356

JCO.2005.04.6037

P1433

Journal of Clinical Oncology

P1476

Alemtuzumab as consolidation a ...... chronic lymphocytic leukemia.

@en

P2093

Alessandra Tedeschi

http://www.w3.org/2001/XMLSchema#string

Anna Colosimo

http://www.w3.org/2001/XMLSchema#string

Barbara Scarpati

http://www.w3.org/2001/XMLSchema#string

Enrica Morra

http://www.w3.org/2001/XMLSchema#string

Francesca Ricci

http://www.w3.org/2001/XMLSchema#string

Liliana Intropido

http://www.w3.org/2001/XMLSchema#string

Marco Montillo

http://www.w3.org/2001/XMLSchema#string

Mario Regazzi

http://www.w3.org/2001/XMLSchema#string

Michela Montagna

http://www.w3.org/2001/XMLSchema#string

Michele Nichelatti

http://www.w3.org/2001/XMLSchema#string

P304

2337-2342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.04.6037

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Silvio Marco Veronese

P577

2006-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16618945

http://www.w3.org/2001/XMLSchema#string

P921